Loading...
XNASBCRX
Market cap1.59bUSD
Jan 10, Last price  
7.67USD
1D
-4.72%
1Q
3.23%
Jan 2017
21.17%
Name

BioCryst Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:BCRX chart
P/E
—
P/S
4.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.25%
Rev. gr., 5y
74.21%
Revenues
331m
+22.37%
336,901151,8676,211,93671,237,90156,561,36974,589,00063,501,00019,643,00026,293,00017,331,00013,608,00048,257,00026,353,00025,186,00020,653,00048,835,00017,812,000157,170,000270,827,000331,412,000
Net income
-227m
L-8.33%
-21,104,121-26,098,768-43,617,853-29,055,524-24,731,570-13,452,000-32,733,000-56,948,000-39,081,000-30,108,000-45,189,000-43,019,000-55,144,000-65,782,000-101,252,000-120,065,000-196,567,000-184,062,000-247,117,000-226,539,000
CFO
-95m
L-41.22%
-18,151,335-23,346,157-15,211,315-24,997,799-20,873,820-16,218,470-28,554,221-32,251,000-37,397,000-26,530,000-38,551,000-13,116,000-53,438,000-41,143,000-92,565,000-89,584,000-137,216,000-142,157,000-161,850,000-95,141,000
Earnings
Feb 24, 2025

Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
URL
https://www.biocryst.com/
IPO date
Mar 04, 1994
Employees
531
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
331,412
22.37%
270,827
72.31%
Cost of revenue
434,767
419,262
Unusual Expense (Income)
NOPBT
(103,355)
(148,435)
NOPBT Margin
Operating Taxes
310
2,733
Tax Rate
NOPAT
(103,665)
(151,168)
Net income
(226,539)
-8.33%
(247,117)
34.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
342
14,955
BB yield
-0.03%
-0.70%
Debt
Debt current
2,648
2,369
Long-term debt
833,735
747,256
Deferred revenue
Other long-term liabilities
Net debt
447,396
289,161
Cash flow
Cash from operating activities
(95,141)
(161,850)
CAPEX
(2,168)
(1,351)
Cash from investing activities
(131,498)
(128,238)
Cash from financing activities
32,485
88,027
FCF
(109,156)
(157,877)
Balance
Cash
388,987
442,387
Long term investments
18,077
Excess cash
372,416
446,923
Stockholders' equity
(1,677,764)
(1,452,716)
Invested Capital
2,047,384
739,137
ROIC
ROCE
EV
Common stock shares outstanding
192,198
185,908
Price
5.99
-47.82%
11.48
-17.11%
Market cap
1,151,266
-46.06%
2,134,224
-13.97%
EV
1,598,662
2,423,385
EBITDA
(101,700)
(146,998)
EV/EBITDA
Interest
108,239
99,092
Interest/NOPBT